Optimizing Time to Treatment to Achieve Durable Biochemical Disease Control after Surgery in Prostate Cancer: A Multi-Institutional Cohort Study
Authors:
- 1 March 2019
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 28 (3) , 570-577
Abstract
Background: The impact of treatment delays on prostate cancer–specific outcomes remains ill-defined. This study investigates the effect of time to treatment on biochemical disease control after prostatectomy. Methods: This retrospective study includes 1,807 patients who received a prostatectomy as a primary treatment at two large tertiary referral centers from 1987 to 2015. Multivariate cox model with restricted cubic spline was used to identify optimal time to receive treatment and estimate the risk of biochemical recurrence. Results: Median follow-up time of the study was 46 (interquartile range, 18–86) months. Time to treatment was subcategorized based on multivariate cubic spline cox model. In multivariate spline model, adjusted for all the pertinent pretreatment variables, inflection point in the risk of biochemical recurrence was observed around 3 months, which further increased after 6 months. Based on spline model, time to treatment was then divided into 0 to 3 months (61.5%), >3 to 6 months (31.1%), and 6 months (7.4%). In the adjusted cox model, initial delays up to 6 months did not adversely affect the outcome; however, time to treatment >6 months had significantly higher risk of biochemical recurrence (HR, 1.84; 95% confidence interval, 1.30–2.60; P < 0.01). Conclusions: The initial delays up to 6 months in prostate cancer primary treatment may be sustainable without adversely affecting the outcome. However, significant delays beyond 6 months can unfavorably affect biochemical disease control. Impact: Time to treatment can aid clinicians in the decision-making of prostate cancer treatment recommendation and educate patients against unintentional treatment delays.Keywords
Funding Information
- American Cancer Society (ACS) (MRSG-17-108-01-TBG)
- Prostate Cancer Foundation (PCF)
- V Foundation for Cancer Research (V Foundation)
- V Foundation for Cancer Research (V Foundation)
This publication has 26 references indexed in Scilit:
- Development and Validation of a Novel Integrated Clinical-Genomic Risk Group Classification for Localized Prostate CancerJournal of Clinical Oncology, 2018
- Comparison of Pathological Outcomes for Men with Low Risk Prostate Cancer from Diverse Practice Settings: Similar Results from Immediate Prostatectomy or Initial Surveillance with Delayed ProstatectomyJournal of Urology, 2016
- Enhancing Value for Patients With Cancer: Time to Treatment as a Surrogate for Integrated Cancer CareJournal of the National Comprehensive Cancer Network, 2016
- Pathologic outcomes for low-risk prostate cancer after delayed radical prostatectomy in the United StatesUrologic Oncology: Seminars and Original Investigations, 2015
- Is increased time to diagnosis and treatment in symptomatic cancer associated with poorer outcomes? Systematic reviewBritish Journal of Cancer, 2015
- African American men with low-grade prostate cancer have increased disease recurrence after prostatectomy compared with Caucasian menUrologic Oncology: Seminars and Original Investigations, 2015
- Effect of delaying surgery on radical prostatectomy outcomes: a contemporary analysisBJU International, 2011
- Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins ExperienceJournal of Clinical Oncology, 2011
- Is delayed radical prostatectomy in men with low‐risk screen‐detected prostate cancer associated with a higher risk of unfavorable outcomes?Cancer, 2010
- Time Trends and Characteristics of Men Choosing Watchful Waiting for Initial Treatment of Localized Prostate Cancer: Results From CaPSUREJournal of Urology, 2003